Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
Understanding Potential Issues of Weight Loss Surgery Bariatric surgery can be a safe and effective intervention for weight loss management when other methods have been unsuccessful
How Tirzepatide Works Tirzepatide activates both GIP and GLP-1 receptors simultaneously
The SURMOUNT-1 trial specifically noted that participants with a BMI of 35 or higher who received the 15mg tirzepatide dose lost an average of 26.5% of their body weight, substantially higher than the overall trial average
Regular consultations with your healthcare provider can help manage side effects and ensure the treatment is tailored to your specific health needs